IPO update: PolyPid files for $24M IPO; DBV sets terms for $98M IPO; Atara prices below the range;

@FierceBiotech: InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs. News | Follow @FierceBiotech

@JohnCFierce: Well that tax inversion business was a lot of fun--I wonder what the next big biopharma M&A trend will be. More | Follow @JohnCFierce

@DamianFierce: IPF drugs from $ITMN and Boehringer Ingelheim win FDA approvals at the same time. | Follow @DamianFierce

@EmilyMFierce: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More from FierceVaccines | Follow @EmilyMFierce

> The Israeli biotech PolyPid, which is developing new drug delivery tech, has filed for a $24 million IPO. SEC filing

> France's DBV Technologies, which is working on a new therapy for food allergies, set its terms for a $98 million IPO. Report

> Atara Biotherapeutics took a haircut on its IPO, pricing shares at $11, well below the range of $14 to $16. The share price quickly slipped once trading began. Story

> Toronto-based Highland Therapeutics has raised $25 million. Release

Medical Device News

@FierceMedDev: Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Advisory board recommends that Arkansas Medicaid cut restrictions on $VRTX's cystic-fibrosis drug Kalydeco. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. FierceDrugDelivery article | Follow @MichaelGFierce

> Agilent axes 300 employees to focus on applied markets and diagnostics businesses. More

> Wearable sensor shown effective in preventing bedsores. Story

> Medtronic scores victory in ongoing patent war with Mirowski. Article

Pharma News

@FiercePharma: Top-read in FiercePharmaMarketing Weds: World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Article | Follow @FiercePharma

@EricPFierce: Remember when FDA asked heparin makers to test APIs for OCSC? This warning letter to a Chinese co. is why. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Have you seen FP's latest report? The top 10 most expensive drugs of 2013. Feature | Follow @CarlyHFierce

> AbbVie calls it quits on $55B Shire takeover. News

> Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%. Article

Vaccines News

> Sanofi inks pact with Immune Design to boost herpes vax effort. Story

> Bexsero could be cost-effective for England, model says--but not at Novartis' price. Report

> Sanofi, Selecta join hands in diabetes vaccine push. Article

> NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. More

> Sanofi takes rotavirus vax into Phase III with eye on Indian market. Story

Pharma Manufacturing News

> FDA bans maker of suspect Chinese heparin. More

> Court orders Indian drugmaker to destroy $11M worth of unapproved drugs. Story

> FDA cites animal drug compounder for selling copies of Novartis' Capstar. Item

> Italy's Cosmos to build manufacturing plant in Ireland. News

> Abbott opens third nutrition plant this year. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.